These real-world data add important information to appropriate PSMA-PET/CT-staged patients receiving an individual RT concept radiating all PET-positive tumor sites and demonstrates the excellent tolerability with favorable risk–benefit profile. The gene discussed is FOLH1; the disease is neoplasm.